Safety and Efficacy of Subcutaneous Daratumumab

Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL ...

Expert opinion: SC daratumumab is preferred over IV daratumumab, but the clinical situation ultimately should determine route of administration.

Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL ...

SC daratumumab appears to deliver the same disease benefit as IV daratumumab to patients with decreased infusion-related reactions (IRRs), decreased time for ...

Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal ...

Subcutaneous daratumumab, an anti-myeloma monoclonal antibody, is administered at a fixed dose of 1800 mg with similar efficacy compared with ...

Subcutaneous Daratumumab is Safe and Tolerable in Multiple ...

Findings from the phase 3 PERSEUS study found the safety profile of D-VRd in newly diagnosed multiple myeloma to be in line with the known profiles of the ...

Subcutaneous Delivery of Daratumumab Is Safe, Effective in ...

According to results from the open-label, multicenter, dose-escalation phase Ib PAVO study, subcutaneous administration of the anti-CD38 ...

Subcutaneous daratumumab in patients with relapsed or refractory ...

Abstract. Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation ...

Efficacy and safety of the randomized, open-label, non-inferiority ...

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration ...

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

In 2020, subcutaneous (SC) daratumumab was approved for the treatment of multiple myeloma, and randomized data suggest a lower rate of IRRs compared with IV ...

Subcutaneous Daratumumab Demonstrates Efficacy Similar to IV ...

In patients with heavily pretreated relapsed or refractory multiple myeloma, subcutaneous daratumumab (DARA SC) demonstrated efficacy similar to the IV ...

Subcutaneous Versus IV Daratumumab May Be a Preferred ...

Further research is needed to determine the tolerability, safety, and efficacy of subcutaneous daratumumab in combination with other therapies ...

Subcutaneous daratumumab: combining efficacy, safety ...

ASCO 2018 | Subcutaneous daratumumab: combining efficacy, safety & convenience ... IV administration of daratumumab has several issues, including ...

Safety of subcutaneous daratumumab in the treatment of plasma ...

Secondary outcomes include timing and severity of IRRs based on CTCAE version 4.0. Results: A total of 82 patients received SC Dara during the ...

Daratumumab-Based Treatment for Immunoglobulin Light-Chain ...

In the phase 3 ANDROMEDA trial, we evaluated the safety and efficacy of subcutaneous daratumumab plus bortezomib, cyclophosphamide, and ...

Subcutaneous Daratumumab for Multiple Myeloma

Pivotal Clinical Trial Conclusions. Collectively, the findings from the COLUMBA and PLEIADES trials supported comparable safety and efficacy of SC daratumumab ...

Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL ...

that daratumumab may depress fetal immunity and decrease fetal bone density. ... eight doses, then every two weeks for doses 9–16, then every ...

Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI

In the 2020 trial, daratumumab was given through intravenous infusions. But since then, subcutaneous injections have been preferred, Dr.

Subcutaneous daratumumab: combining efficacy, safety ... - YouTube

IV administration of daratumumab has several issues, including a long infusion time (~7 h) and the likelihood of infusion-related toxicities ...

Articles Subcutaneous versus intravenous daratumumab in patients ...

Subcutaneous daratumumab was non-inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in ...

Evaluation of administration-related reactions with subcutaneous ...

Dara-SQ was shown to be non-inferior to intravenous daratumumab (Dara-IV) in efficacy, safety, and associated with fewer administration-related reactions (ARRs ...

Subcutaneous versus intravenous administration of daratumumab in ...

It was found that subcutaneous daratumumab was not inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics. However, subcutaneous ...